Royalty Pharma plc (NASDAQ:RPRX) Position Boosted by Lindbrook Capital LLC

Lindbrook Capital LLC grew its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 485.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,411 shares of the biopharmaceutical company’s stock after purchasing an additional 1,999 shares during the period. Lindbrook Capital LLC’s holdings in Royalty Pharma were worth $68,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in RPRX. Allworth Financial LP boosted its position in shares of Royalty Pharma by 89.8% during the 3rd quarter. Allworth Financial LP now owns 953 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 451 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Royalty Pharma by 112.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 531 shares in the last quarter. Rakuten Securities Inc. bought a new position in shares of Royalty Pharma during the 4th quarter valued at about $110,000. CWM LLC boosted its position in shares of Royalty Pharma by 75.9% during the 3rd quarter. CWM LLC now owns 4,782 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 2,064 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in shares of Royalty Pharma by 10.8% during the 3rd quarter. PNC Financial Services Group Inc. now owns 5,509 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 536 shares in the last quarter. Institutional investors own 54.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on RPRX shares. Bank of America reduced their price objective on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, April 12th. The Goldman Sachs Group reduced their price objective on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 20th. JPMorgan Chase & Co. reduced their price objective on shares of Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a research note on Tuesday, February 20th. Finally, StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, April 11th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Royalty Pharma presently has an average rating of “Buy” and a consensus price target of $46.75.

Royalty Pharma Price Performance

NASDAQ RPRX opened at $27.98 on Thursday. The company has a 50 day simple moving average of $29.69 and a 200-day simple moving average of $28.54. The company has a debt-to-equity ratio of 0.61, a current ratio of 7.90 and a quick ratio of 7.90. The firm has a market capitalization of $16.72 billion, a price-to-earnings ratio of 14.80 and a beta of 0.45. Royalty Pharma plc has a 52-week low of $25.92 and a 52-week high of $35.95.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.12. The business had revenue of $736.00 million during the quarter, compared to analyst estimates of $702.90 million. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. Equities research analysts predict that Royalty Pharma plc will post 3.95 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 17th will be given a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date of this dividend is Thursday, May 16th. Royalty Pharma’s dividend payout ratio (DPR) is 44.44%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.